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What about autoantibodies against interferon-beta?
Interferon-beta (b-IFN) represents the first-line immunomodulatory treatment for patients with relapsing-remitting multiple sclerosis (MS). However, over the last decade increaseda wareness of autoantibodies against b-IFN has emerged. These may develop in av ariablep ercentage of treated subjects (2-45%), depending on the b-IFN compound and the assay method, and impair the therapeutic efficacy of interferons [1] . Recent European guidelines recommend measurement of neutralizing antibodies to be performed in all patients at 12 and 24 months of therapy, in specialized laboratories with validated methods. Follow-up of titers is not judged necessary in subjects who remain negative during this period, but therapy with b-IFN should be discontinued in those with high titers [2] ; however, controversies with North American experts exist [3] .
In this context, two recent studies carried out in Scandinavia attempted to investigate the natural course and the impact of steroids on these autoantibodies. In order to determine spontaneous titers' fluctuation over time, aS wedish group investigated, retrospectively, ac ohort of 822 MS patients treated with the three commercially available b-IFN compounds, who benefited from at least two autoantibodies testing at one year interval or more. They chose ac utoff of 150 TRU/ml for biological relevancy [4] . Overall, 72% of patients did not show any titer variation between the assays. This percentage was even higher in subjects at the two extremes (i.e., 97% with no antibodies, 91% with very high titers), while those with moderate titers tended to fluctuate more often. This trend was not influenced by treatment duration, b-IFN type, or the length of sampling interval. Interestingly, ad ecrease over time in antibodies titers appeared more often than an increase. The study was somewhat limited by its selection bias, and the use of laboratory assays prevents direct comparisons with other studies [5] . Nevertheless, these results may further support the practice of discontinuing b-IFN administration in subjects with high titers, and suggest some usefulness of repeated measurements in patients in the "grey zone".
AD anish team designed an on-randomized interventional trial to assess the usefulness of the co-administration of 500mgofmethylprednisolone orally (three days monthly, for6months) in subjects with positive autoantibodies (cutoff not clear) combined with an absent in vivo response to b-IFN (tested using acytopathic effect assay) [6] . There were 35 patients in the treatment sample, and 38 controls (subjects that chose not to undergo steroid administration and
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Neuroimaging This 44-year-old man had his first generalized convulsion at the age of 28, and from then he started to take carbamazepine 400 mg b.i.d. Since that time, he has complained of occasional (about one per month) spells with loss of contact, preceded at times by asensation of aparticular, stereotyped religious thought, which he can not further characterize. The EEG showsafrontal irregular slowing without clear lateralization. What areyour thoughts after looking at the MRI?
Correspondence: Dr. Andrea O. Rossetti Service de neurologie CHUV CH-1011 Lausanne e-mail: Andrea.Rossetti@chuv.hospvd.ch were given glatirameracetate [29 patients], or discontinued immunomodulatory treatment). Both groups were relatively similar, except for ah igher proportion of men in the treatment group. At a6m onth follow-up, 21% of patients treated with methylprednisolone, and 11% in the control group regained an in vivo response to b-IFN (p =0.35); also the percentage of patients experiencing arelapse during the study periodw as notd ifferent (18% vs 26%, p=0 .56). The authors concluded that these results do not suggest any benefit of steroids co-administration in patients with positive autoantibodies titers; however, this does not formally exclude apossible effect if immunosuppressive treatment is given at an earlier time point. As partly acknowledged by the authors, this studyappears underpowered. Furthermore, the lack of randomizationand the different treatment regimens among the two groups (i.e., the use of glatirameracetate) are of concern. The editorial also points out that, to date, no solid evidence shows that the in vivo assessment used in this trial correlates with the clinical response [7] . In fact, ap reliminary observation from New Jersey suggests that identification of patients at risk of developing antibodies against b-IFN is possible by screening for "binding" antibodies repetitively in the first 12 months of treatment. These seem to develop earlier than "neutralizing" antibodies, and administration of methylprednisolone at this early time appears beneficial [8] .
The management of patients developing autoantibodies to b-IFN remains challenging. Switching between different b-IFN compounds does not appear to represent avalid solution, as antibodies' cross-reactivity has been demonstrated, and strategies to remove autoantibodies (such as plasma exchange or IVIG), or variousc ombinations with other immunosuppressive agents, do not have any clear evidence of efficacy [7] . While achange to glatirameracetate is commonly used in this setting, further investigations are clearly needed to identify the best strategy. MCQ 1. Which of the following statements is correct regarding anisocoria? AT he wider pupil lateralizes the lesion. BT he smaller pupil lateralizes the lesion. CT he swing-flash-light test is very helpful to detect an efferent deficit. DI ncrease of the pupils' difference in darkness is characteristic of aHorner syndrome. EI ncrease of the pupils' difference in darkness is characteristic of aparasympathetic deficit.
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Please indicate the wrong sentence:
AA fter athorough analysis, most ictal headaches result in being benign. BH ypnic headache may interfere with sleep. C" SUNCT" is practically always unilateral. DA "sentinel" headache may precede, by hours or days, catastrophic aneurysmal bleeding. EA history of smoking does not correlate with the prevalence of cluster headaches.
3. Please indicate the correct statement related to the treatment of acute ischemic stroke: AT he time window for IV thrombolysis has been recently widened to 4.5 hb ecause the efficacy remains constant over this time lapse. BB efore IV thrombolysis, arterial pressure should always be quickly lowered below 150/80 mm Hg with labetolol. CA fter IV thrombolysis, it is better to wait 2-3 hb efore administering antiplatelet agents. D" Malignant" ACM ischemia presents more often in elderly people. EC onsidering the "odds ratios", decompressive craniotomy represents the most efficacious treatment for survival afteracute stroke.
Which of the following statements regarding status epilepticus (SE) is correct?
AS ince most complex-partial seizures last for more than 4m inutes, it is premature to consider SE after 5minutes. BS Er efractory to 2t reatment lines should always be treated with coma induction. CT he most common etiologies in adults are cerebrovascular diseases and drug withdrawal. DT he drug of choice for initial treatment is phenytoin, since it does not impair consciousness. ET he most important prognostic predictors are gender and ethnicity. 
Neuroimage answer
At the left fronto-polar region, one may notice that the cortical-subcortical differentiation appears less sharp than in other areas. Furthermore, the cortex seems thinner and more hyperintense. Finally, there is ahalo of hyperintensity directing towards the frontal horn of the lateral ventricle. This "transmantle" signal of abnormality, which is somewhat better seen on the T1 image (below), is aclassic finding in focal cortical dysplasia. These abnormalities are highly epileptogenic.
As ar elatively rare but characteristic element, this patient describes an aura that may suggest a"forced thinking", af eature that has been reported to occur with dominant epileptic foci (i.e., mostly left-sided). After the carbamazepine dose was increased to 1000 mg per day, he remained seizurefree (more than one year follow-up).
MCQ Answer key:
1. D 2. E 3. E 4. C 5. B
